Skeletal muscle regeneration depends on coordinated transitions of muscle stem cells (MuSCs), also known as satellite cells, from quiescence through activation and proliferative expansion to differentiation and fusion, while self-renewal replenishes the quiescent MuSC pool within a dynamically remodeled niche. Fibroblast growth factor (FGF) signaling regulates these transitions, but its effects vary as MuSCs and their niche change across regenerative stages. FGF output is shaped by ligand availability and extracellular presentation, fibroblast growth factor receptor (FGFR) isoform expression and coreceptor availability, receptor trafficking, intracellular feedback, and the state of the responding cell. Following acute injury, FGF inputs can support MuSC activation and expansion; signaling is subsequently reconfigured during differentiation, fusion, self-renewal, and return to quiescence. Aging-associated regenerative decline, chronic injury and dystrophic remodeling, denervation, and metabolic dysfunction disrupt this coordination and can uncouple FGF activity from productive repair. Rhabdomyosarcoma provides a distinct malignant context in which the FGF network is rewired to sustain oncogenic myogenic cell states. Here, we integrate molecular, cellular, and niche-level evidence across these settings to explain why FGF signaling produces divergent outcomes and to clarify how cellular context and timing should inform therapeutic modulation.
Hemophagocytic lymphohistiocytosis (HLH) is a severe immunological disorder characterized by dysregulated immune activation. Pathogenic variants in HLH-causative genes serve as diagnostic criteria and guide treatment decisions. However, known genes do not fully explain the molecular basis of many cases, and the polygenic contribution to HLH susceptibility remains poorly characterized. Here, we retrospectively analyzed whole-exome sequencing data from 1241 patients with clinically diagnosed or suspected HLH to characterize the HLH genetic landscape. Rare variant association analysis identified two candidate susceptibility genes,
IKBKG
and
DDX3X
. Functional experiments showed that
IKBKG
knockdown impaired NK cell cytotoxicity and degranulation, supporting a contributory role of
IKBKG
in HLH-related immune dysfunction. Exploratory common variant analysis identified potential susceptibility loci, and an integrated model incorporating rare variant burden and polygenic risk score achieved an AUC of 0.71 in this cohort. These findings expand understanding of HLH genetic architecture and support contributions from both rare and common variants.